Author

Bradley Balk

Roswell Park Comprehensive Cancer Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Boyko S. AtanassoviD· 1 shared Collin M. Blakely· 1 shared David W. GoodrichiD· 1 shared Eduardo Cortes GomeziD· 1 shared Elizaveta V. BenevolenskayaiD· 1 shared Jianmin WangiD· 1 shared Justine J. JacobiiD· 1 shared Letian Zhang· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Boyko S. AtanassovORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Reversible therapeutic resistance in EGFR mutant lung cancer caused by RB1 loss induced lineage plasticity

Letian Zhang, Meenalakshmi Chinnam, Bradley Balk, Xiaojing Zhang, Yanqing Wang, Tatiana Shaurova, Shamshad Alam, Saraswati Pokharel, Prashant Singh, Justine J. Jacobi, Jianmin Wang, Eduardo Cortes Gomez, Michael Habitzruther, Mukund Seshadri, Boyko S. Atanassov, , David W. Goodrich

This study shows RB1 loss in EGFR mutant lung cancer leads to reversible lineage plasticity, accelerating resistance to EGFR TKI therapy through non-genetic mechanisms.

bioRxiv · Aug 4, 2025 · PreprintCancer Biology